A health carrier may not reclassify benefits with respect to cancer treatment medications or increase a copayment, deductible, or coinsurance amount for covered cancer treatment medications that are injected or intravenously administered unless:

(1) The increase is applied generally to other medical or pharmaceutical benefits covered under the plan and is not done to circumvent § 58-17H-50;

(2) The reclassification of benefits with respect to cancer treatment medications is done in a manner that is consistent with §§ 58-17H-50 to 58-17H-52, inclusive; or

(3) A health carrier is applying cost-sharing increases consistent with the annual increases in the cost of health care.

Source: SL 2015, ch 252, § 2, eff. Jan. 1, 2016.